article-journal

EU-SolidAct
European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial Hosted on the Open Science Framework
Inge Christoffer Olsen, Thale Patrick-Brown, Marius Trøseid
Cite DOI URL
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial
OBJECTIVE: To evaluate and compare benefits and harms of three biological treatments with different modes of action versus active …
Merete Lund Hetland, Espen A. Haavardsholm, Anna Rudin, Dan Nordström, Michael Nurmohamed, Bjorn Gudbjornsson, Jon Lampa, Kim Hørslev-Petersen, Till Uhlig, Gerdur Grondal, Mikkel Østergaard, Marte S. Heiberg, Jos Twisk, Kristina Lend, Simon Krabbe, Lise Hejl Hyldstrup, Joakim Lindqvist, Anna-Karin Hultgård Ekwall, Kathrine Lederballe Grøn, Meliha Kapetanovic, Francesca Faustini, Riitta Tuompo, Tove Lorenzen, Giovanni Cagnotto, Eva Baecklund, Oliver Hendricks, Daisy Vedder, Tuulikki Sokka-Isler, Tomas Husmark, Maud-Kristine Aga Ljoså, Eli Brodin, Torkell Ellingsen, Annika Söderbergh, Milad Rizk, Åsa Reckner Olsson, Per Larsson, Line Uhrenholt, Søren Andreas Just, David John Stevens, Trine Bay Laurberg, Gunnstein Bakland, Inge C. Olsen, Ronald van Vollenhoven, NORD-STAR study group
Cite DOI
A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics
Here, we randomized 53 patients hospitalized with coronavirus disease 2019 (COVID-19) to hydroxychloroquine therapy (at a dose of 400 …
Magnus Nakrem Lyngbakken, Jan-Erik Berdal, Arne Eskesen, Dag Kvale, Inge Christoffer Olsen, Corina Silvia Rueegg, Anbjørg Rangberg, Christine Monceyron Jonassen, Torbjørn Omland, Helge Røsjø, Olav Dalgard
Cite DOI
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials
BACKGROUND: The NOR-SWITCH main and extension trials demonstrated that switching from originator to biosimilar infliximab (CT-P13) is …
Kristin K. Jørgensen, Guro L. Goll, Joe Sexton, Nils Bolstad, Inge C. Olsen, Øivind Asak, Ingrid P. Berset, Ingrid M. Blomgren, Katrine Dvergsnes, Jon Florholmen, Svein O. Frigstad, Magne Henriksen, Jon Hagfors, Gert Huppertz-Hauss, Espen A. Haavardsholm, Rolf A. Klaasen, Bjørn Moum, Geir Noraberg, Ulf Prestegård, Jan H. Rydning, Liv Sagatun, Kathrine A. Seeberg, Roald Torp, Cecilia Vold, David J. Warren, Carl M. Ystrøm, Knut E. A. Lundin, Tore Kvien, Jørgen Jahnsen
Cite DOI
Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial
OBJECTIVES: The hypothesis of the study is that treatment with hydroxychloroquine sulphate in hospitalised patients with coronavirus …
Magnus Nakrem Lyngbakken, Jan-Erik Berdal, Arne Eskesen, Dag Kvale, Inge Christoffer Olsen, Anbjørg Rangberg, Christine Monceyron Jonassen, Torbjørn Omland, Helge Røsjø, Olav Dalgard
Cite DOI
Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs
BACKGROUND: Scaled-up direct-acting antiviral (DAA) treatment of hepatitis C virus (HCV) infection among people who inject drugs (PWID) …
H. Midgard, A. K. Finbråten, K. B. Malme, R. M. Berg-Pedersen, L. Tanum, I. C. Olsen, R. Bjørnestad, O. Dalgard
Cite DOI
Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial
BACKGROUND: Skin emollients applied during early infancy could prevent atopic dermatitis, and early complementary food introduction …
Håvard Ove Skjerven, Eva Maria Rehbinder, Riyas Vettukattil, Marissa LeBlanc, Berit Granum, Guttorm Haugen, Gunilla Hedlin, Linn Landrø, Benjamin J. Marsland, Knut Rudi, Kathrine Dønvold Sjøborg, Cilla Söderhäll, Anne Cathrine Staff, Kai-Håkon Carlsen, Anna Asarnoj, Karen Eline Stensby Bains, Oda C. Lødrup Carlsen, Kim M. Advocaat Endre, Peder Annæus Granlund, Johanne Uthus Hermansen, Hrefna Katrín Gudmundsdóttir, Katarina Hilde, Geir Håland, Ina Kreyberg, Inge Christoffer Olsen, Caroline-Aleksi Olsson Mägi, Live Solveig Nordhagen, Carina Madelen Saunders, Ingebjørg Skrindo, Sandra G. Tedner, Magdalena R. Værnesbranden, Johanna Wiik, Christine Monceyron Jonassen, Björn Nordlund, Karin C. Lødrup Carlsen
Cite DOI
The Labour Progression Study (LaPS): Duration of labour following Zhang's guideline and the WHO partograph - A cluster randomised trial
OBJECTIVE: To investigate labour duration in different phases of labour when adhering to Zhang’s guideline for labour progression …
Rebecka Dalbye, Ellen Blix, Kathrine Frey Frøslie, Jun Zhang, Torbjørn Moe Eggebø, Inge Christoffer Olsen, Daniella Rozsa, Pål Øian, Stine Bernitz
Cite DOI
Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)
BACKGROUND: Infliximab (INX) and other tumour necrosis factor inhibitors (TNFi) have revolutionised the treatment of several immune …
Silje W. Syversen, Guro L. Goll, Kristin K. Jørgensen, Inge C. Olsen, Øystein Sandanger, Johanna E. Gehin, David J. Warren, Joseph Sexton, Cato Mørk, Jørgen Jahnsen, Tore K. Kvien, Nils Bolstad, Espen A. Haavardsholm
Cite DOI
Comment on: Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry: reply
Inge Christoffer Olsen
Cite DOI